Public funding
2024-2026Fundamental principles for the development of small-molecule blockers of virus-host cell interactionsRussian Science Foundation (RSF), Russia
2021-2023Bringing mycobacterial secretion inhibitors to maturationNetherlands Antibiotic Development Platform (NADP), Netherlands
2021-2023Virulence factors of Mycobacterium tuberculosis as a new target for small molecules with the prospect of developing drugs with an original mechanism of actionRussian Science Foundation (RSF), Russia
2021-2022Drug candidate PDSTP for use in the prevention and treatment of viral infections caused by SARS-CoV-2Ministry of Science and Higher Education of the Russian Federation, Russia2019-2023New weapons against Mycobacterium abscessus and other nontuberculous mycobacteriaItalian Cystic Fibrosis Research Foundation (FCC), Italy
2021-2022Multidisciplinary platform based on artificial intelligence for accelerating drug discovery and repurposing for COVID-19Russian Foundation for Basic Research (RFBR), Russia
2017-2019New generation of non-nucleoside reverse transcriptase HIV inhibitors avoiding HIV-associated neurocognitive disordersRFBR — National Institute of Allergy and Infectious Diseases, Russia-USA
2017-2019Thienopyrimidines highly active against Mycobacterium tuberculosis: target identification and mechanism-of-action studyRFBR, Russia
2016-2018Design, synthesis and mode-of-action study of new original heterocyclic compounds with activity on latent tuberculosis infectionMinistry of Science and Higher Education of the Russian Federation, Russia2016-2018New inhalable compounds against the CF pathogen Burkholderia cenocepaciaCystic Fibrosis Foundation, USA
2013-2020Pre-clinical studies on a heparan receptor-blocking compound for the treatment of herpesvirus infections, including their generalized formsPharma-2020 Strategy, Ministry of Industry and Trade of the Russian Federation, Russia
2011-2016More Medicines for Tuberculosis (MM4TB)The 7th Research Framework Programme, European Commission, EU2006-2010New Medicines for Tuberculosis (NM4TB)The 6th Research Framework Programme, European Commission, EU